COLL FINANCIAL STATEMENTS

Collegium Pharmaceutical Inc — balance sheet, income statement and cash flow trends

COLLCollegium Pharmaceutical Inc

🇺🇸 USA · NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic

Value it Duel

Income Statement

Quarterly progression — trailing-twelve-month values

RevenueNet Income

Profit Funnel

Q1 2026 · TTM

Percentages are relative to revenue.

Key Figures

YoY change

Revenue796.3 M $+19.9%

Gross Profit483.2 M $+26.1%

Operating Income189.9 M $+33.6%

EBITDA609.9 M $+83.3%

Net Income74.9 M $+70.7%

Peer Comparison· Drug Manufacturers - Specialty & Generic

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
COLL	19.9%	60.7%	76.6%	9.4%
BHC	-9.9%	75.9%	60.0%	-13.5%
ECILC	-2.3%	34.3%	14.8%	-3.6%
GENIL	16.3%	23.4%	14.3%	4.0%
ROVI	-3.4%	63.2%	27.0%	17.8%
HLN	-26.7%	61.5%	25.2%	12.6%
Industry median	7.5%	60.6%	18.2%	4.0%

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
COLL	19.9%	60.7%	76.6%	9.4%
XERS	41.5%	81.6%	14.7%	3.8%
PRGO	-3.6%	34.2%	-29.7%	-43.5%
HROW	26.2%	74.1%	11.7%	-5.6%
PAHC	26.0%	32.5%	15.0%	6.3%
ANIP	37.0%	65.9%	25.4%	9.7%
Industry median	7.5%	60.6%	18.2%	4.0%

Balance Sheet

Quarterly period-end values

Total AssetsTotal LiabilitiesEquity

Capital Structure

Q1 2026

Equity312.4 M $19%
Current Liabilities435 M $26%
Long-term Liabilities904.6 M $55%

Key Figures

YoY change

Total Assets1.7 B $+1.3%

Total Liabilities1.3 B $-4.1%

Total Equity312.4 M $+33.3%

Cash & ST Investments421.8 M $+113.2%

Total Debt808.1 M $-4.3%

Net Debt539.4 M $-27.9%

Peer Comparison· Drug Manufacturers - Specialty & Generic

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
COLL	1.71	258.6%	0.63	18.9%
BHC	1.32	-1,010.0%	3.71	-8.4%
ECILC	1.73	5.9%	-0.10	81.0%
GENIL	1.33	41.0%	1.10	52.6%
ROVI	3.66	17.0%	0.09	72.8%
HLN	0.92	52.3%	3.50	50.3%
Industry median	2.22	46.3%	1.24	45.7%

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
COLL	1.71	258.6%	0.63	18.9%
XERS	2.12	286.9%	-1.61	3.3%
PRGO	2.72	152.3%	-2.78	31.3%
HROW	2.48	1,047.4%	6.55	6.8%
PAHC	3.17	217.6%	3.15	25.0%
ANIP	3.12	58.3%	0.07	39.5%
Industry median	2.22	46.3%	1.24	45.7%

Cash Flow Statement

Quarterly progression — trailing-twelve-month values

Operating Cash FlowCapital ExpendituresFree Cash Flow

Cash Flow Bridge

Q1 2026 · TTM

Key Figures

YoY change

Operating Cash Flow331 M $+66.8%

Capital Expenditures1.2 M $-35.6%

Free Cash Flow329.8 M $+67.8%

Dividends Paid——

Peer Comparison· Drug Manufacturers - Specialty & Generic

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
COLL	41.6%	41.4%	0.2%	441.7%
BHC	16.2%	11.3%	4.9%	-119.7%
ECILC	13.9%	16.1%	7.1%	-391.0%
GENIL	6.4%	-6.7%	4.8%	162.4%
ROVI	24.4%	15.5%	8.9%	137.0%
HLN	12.5%	11.3%	1.2%	99.0%
Industry median	15.2%	11.6%	2.5%	84.3%

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
COLL	41.6%	41.4%	0.2%	441.7%
XERS	15.4%	15.0%	0.4%	404.1%
PRGO	4.5%	2.6%	2.0%	-10.4%
HROW	5.7%	5.3%	0.3%	-101.6%
PAHC	4.4%	0.9%	3.6%	69.4%
ANIP	22.6%	17.4%	5.2%	232.7%
Industry median	15.2%	11.6%	2.5%	84.3%

Amounts are in the company’s reporting currency. Peer comparison tables use ratio-based metrics so currency differences do not distort the picture.

Go deeper on COLL

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 6, 26. This content is for informational purposes only and is not investment advice.